MiMedx Group Inc  

(Public, NASDAQ:MDXG)   Watch this stock  
-0.40 (-4.12%)
Sep 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.19 - 9.71
52 week 6.81 - 13.20
Open 9.44
Vol / Avg. 0.00/1.43M
Mkt cap 1.06B
P/E 62.30
Div/yield     -
EPS 0.15
Shares 108.91M
Beta 1.06
Inst. own 50%
Oct 28, 2015
Q3 2015 MiMedx Group Inc Earnings Release (Estimated) Add to calendar
Aug 12, 2015
MiMedx Group Inc at Canaccord Genuity Growth Conference
Aug 6, 2015
Q2 2015 MiMedx Group Inc Earnings Release
Jul 30, 2015
Q2 2015 MIMEDX GROUP INC Earnings Conference Call - Webcast
Jul 28, 2015
MiMedx Group Inc Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 11.89% 5.26%
Operating margin 12.37% 6.01%
EBITD margin - 7.80%
Return on average assets 19.80% 6.41%
Return on average equity 24.25% 7.64%
Employees 386 -
CDP Score - -


1775 W Oak Commons Ct
MARIETTA, GA 30062-2254
United States - Map
+1-678-3846720 (Phone)
+1-678-3846720 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Company's biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program, mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant, which is referred as an allograft. MiMedx is the supplier of amniotic tissue, having supplied over 350,000 allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.

Officers and directors

Parker H. Petit Jr. Chairman of the Board, Chief Executive Officer
Age: 75
Bio & Compensation  - Reuters
William Charles Taylor President, Chief Operating Officer, Director
Age: 46
Bio & Compensation  - Reuters
Michael J. Senken Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Alexandra O. Haden General Counsel, Secretary
Age: 40
Bio & Compensation  - Reuters
Charles E. Koob Director
Age: 70
Bio & Compensation  - Reuters
Joseph G. Bleser Independent Director
Age: 69
Bio & Compensation  - Reuters
J. Terry Dewberry Independent Director
Bio & Compensation  - Reuters
Charles R. Evans Independent Director
Age: 68
Bio & Compensation  - Reuters
Bruce L. Hack Independent Director
Age: 66
Bio & Compensation  - Reuters